Skip to main content

People in the News: BioRad, Nanosphere

Premium

BioRad Laboratories stockholders have re-elected Louis Drapeau and Albert Hillman as class A directors, and Deborah Neff, Alice Schwartz, and Norman Schwartz as class B directors.


Nanosphere announced the appointment of Ken Bahk as its chief strategy officer, a new position, and that CTO Tim Patno and board member Chad Mirkin will be leaving the company.

Bahk was part of Nanosphere's initial team, and served with the company until 2008. In his new role at Nanosphere, he will be responsible for driving strategic plans and revenues in molecular diagnostics.

He is currently a director of investments at Lurie Investments and previously served as the chair of strategic opportunities for the Association for Molecular Pathology.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.